Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective study

Mir, Seyed Mostafa; Tahamtan, Alireza; Nikoo, Hadi Razavi; Arabi, Mehdi Sheikh; Moradi, Abdul Wahab; Ardakanian, Saeed; Tabarraei, Alijan

doi:10.1016/j.genrep.2021.101448

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombocytopenia, lymphopenia, and anemia have been associated with the worse clinical outcomes in COVID-19 [ 36 ]. Biochemical parameters such as creatinine, urea, lactate dehydrogenase (LDH), liver function tests (LFTs), and creatine kinase (CK) are linked to the severity of COVID-19, and higher values of these parameters reflect a worse outcome [ 37 ]. In this study, we suggest that the administration of MSCs alone or with their EVs is not associated with significant alterations in laboratory outcomes.…”

Section: Discussionmentioning

confidence: 99%

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

Background and aims The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients. Materials and methods COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × 106 cells) or one dose of MSCs (100 × 106 cells) followed by one dose of MSC-derived extracellular vesicles (EVs). Patients were assessed for safety and efficacy by evaluating clinical symptoms, laboratory parameters, and inflammatory markers at baseline and 48 h after the second intervention. Results A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14–1.11; P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005–1.26; P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041). Conclusion MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073.

show abstract

Section: Discussionmentioning

confidence: 99%

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In the second stage and in the pulmonary phase which is the most severe stage; ALT and AST levels increase. In the third hyperinflammatory stage, biochemical parameters such as cTn, BNP, cytokines and creatinine increase (Ciaccio & Agnello, 2020;Mir et al, 2022). In COVID-19; coagulation is increased as a result of increased levels of prothrombotic factors.…”

Section: Discussionmentioning

confidence: 99%

Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients

Gul

Kurt

Çapraz

et al. 2023

Sabuncuoglu Serefeddin Health Sciences

View full text Add to dashboard Cite

The 2019 coronavirus disease (COVID-19) has caused millions of cases worldwide. As the pandemic progresses, understanding the effects of this disease remains important. We aimed to examine the hematological effects of the disease. The research was carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. While PT and INR were found to significantly higher in patients using favipiravir (p

show abstract

“…1,13,14 In the current study, inflammatory markers CRP, IL-6, serum ferritin and D-dimer were found to be significantly raised in patients with severe disease, which is in agreement with earlier studies. 14,15 Bairwa et al reported significant difference with respect to CRP, procalcitonin and lactate dehydrogenase (LDH) between COVID-19 survivors and non-survivors. 4 Other studies have also reported IL-6 and CRP as significantly high in severe disease group.…”

Section: Discussionmentioning

confidence: 99%

Comparison of inflammatory markers in COVID-19 patients- a study based on disease severity groups

Riaz,

Mahmood,

Sattar

et al. 2023

J Pak Med Assoc

View full text Add to dashboard Cite

Objective: To compare different inflammatory markers in various coronavirus disease 2019 severity groups. Method: The cross-sectional, retrospective, comparative study was conducted at the Central Park Teaching Hospital, Lahore, Pakistan, and comprised data from April to June 2021 of coronavirus disease 2019 inpatients. The data was divided into mild, moderate and severe/critical category using the World Health Organisation interim guidelines. Data was analysed using SPSS 22. Results: Of the 50 patients, 29(58%) were males and 21(42%) were females. The overall mean age was 54.12±21.23 years. The mean age was 62±17.1years in critical group compared to 50±19.7 years in mild and 52±15.9 years in moderate groups. There were 8(16%) patients in the mild group, 16(32%) moderate and 26(52%) in the critical severity group. Mortality was the outcome in 19(38%) cases, and 14(73.7%) of them were in the critical group (p=0.03). C reactive protein, interleukin-6, serum ferritin and D-dimer levels were significantly different among the groups (p<0.05). Conclusion: Older people were found to have experienced coronavirus disease 2019 in more severe forms. The inflammatory markers were significantly high in patients with severe disease and were associated with high mortality. Key Words: COVID-19, SARS CoV-2, SARS coronavirus, C-reactive protein, Ferritin, Interleukin-6, Acute-phase protein, Severity of illness.

show abstract

Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective study

Cited by 7 publications

References 25 publications

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients

Comparison of inflammatory markers in COVID-19 patients- a study based on disease severity groups

Contact Info

Product

Resources

About